Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)

NSE:AKUMS Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	45,040	43,614	41,209	41,817	36,572	36,752
Revenue Growth	9.16%	5.83%	-1.45%	14.34%	-0.49%	34.81%
Gross Profit Gross Profit Growth	18,508	17,717	16,216	15,613	13,079	12,607
Operating Income Operating Income Growth	4,116	3,701	3,101	3,590	1,895	3,158
Net Income Net Income Growth	2,917	2,552	3,382	-40.35	948.55	-2,525
Earnings Per Share EPS Growth	19.05	16.67	22.60	-0.28	6.63	-17.65
EPS Growth	-15.15%	-26.26%	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
CDMO CDMO Growth	38,594	37,102	34,402	36,196	31,206	29,776
API API Growth	2,180	2,314	2,771	2,784	2,223	1,361
Domestic Branded Formulations Domestic Branded Formulations Growth	4,541	4,463	4,336	3,985	-	-
International Branded Formulations International Branded Formulations Growth	1,429	1,435	1,426	1,248	-	-
Inter-Segment Inter-Segment Growth	-2,706	-2,727	-2,933	-4,198	-4,430	-3,447
Trade Generics Trade Generics Growth	977.27	1,003	1,179	1,767	-	-
Total Total Growth	45,016	43,590	41,182	41,782	36,548	36,719

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	16,806	16,806	5,683	2,771	1,500	1,028
Total Debt Total Debt Growth	1,917	1,917	1,476	5,652	6,229	3,998
Net Cash (Debt) Net Cash Growth	14,889	14,889	4,208	-2,882	-4,729	-2,969
Net Cash Growth	247.13%	253.85%	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	97.21	97.25	28.12	-20.14	-33.05	-20.76

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	11,812	4,652	4,983	1,766	318.54
Capital Expenditures CapEx Growth	-	-2,305	-2,723	-3,114	-3,288	-2,576
Free Cash Flow Free Cash Flow Growth	-	9,507	1,929	1,869	-1,522	-2,257
Free Cash Flow Growth	-	392.87%	3.23%	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	41.09%	40.62%	39.35%	37.34%	35.76%	34.30%
Operating Margin	9.14%	8.48%	7.52%	8.59%	5.18%	8.59%
Pretax Margin	9.45%	8.76%	8.38%	-1.08%	4.11%	-5.26%
Profit Margin	6.48%	5.85%	8.21%	-0.10%	2.59%	-6.87%
FCF Margin	-	21.80%	4.68%	4.47%	-4.16%	-6.14%

Dividends

Chart

Fiscal Year	Current	FY 2026
Period Ending	Aug 22, 2026	Mar 31, 2026
Dividend Per Share Dividend Per Share Growth	1.000	1.000
Dividend Per Share Growth	0%	-
Dividend Yield	0.13%	0.22%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	39.37	27.96	22.02	-	-	-
Forward PE	25.90	20.30	22.14	-	-	-
P/FCF Ratio	12.08	7.51	38.61	-	-	-
PS Ratio	2.55	1.64	1.81	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 19, 2026

Data Sources Report a data error